BCL6-IN-8c is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC₅₀ of 0.10 µM in cell-free enzyme-linked immunosorbent assay^[1].

IC50: 0.10 µM (B-cell lymphoma 6 (BCL6)-corepressor interaction)^[1]

BCL6-IN-8c (Compound 8c) also exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC₅₀ = 0.72 µM). BCL6-IN-8c does not exhibit significant cytotoxicity even at 30 µM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

The pharmacokinetic profile of BCL6-IN-8c (Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). BCL6-IN-8c exhibits a good pharmacokinetic profile (C_max = 233 ng/mL, T_max = 2 hours, MRT = 3.3 h, AUC = 1.27 mg•h/mL, F (oral bioavailability) = 79.9%)^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

417.84

C₂₀H₂₀ClN₃O₅

2130878-25-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yasui T, et al. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design. Bioorg Med Chem. 2017 Sep 1;25(17):4876-4886.